Neurodegenerative disorders

Controversy rages over aducanumab approval for Alzheimer’s disease

The US Food & Drug Administration (FDA)  approval of aducanumab to treat Alzheimer’s disease has proved controversial, with dementia researchers hailing it as a major step forward while geriatricians have condemned it as premature and lacking sufficient evidence of  benefit. Biogen’s US$56,000/year drug was granted accelerated approval based on surrogate endpoint of reduction of amyloid ...

Already a member?

Login to keep reading.

© 2022 the limbic